Medtronic, Inc. (MDT) PT Lowered to $131 at Needham & Company Following FDA Warning Letter
Tweet Send to a Friend
Needham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $131.00 (from $145.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
